S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
NASDAQ:PROG

Progenity Stock Forecast, Price & News

$1.28
-0.15 (-10.49%)
(As of 01/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.27
$1.46
50-Day Range
$1.24
$4.89
52-Week Range
$0.66
$7.44
Volume
7.60 million shs
Average Volume
11.73 million shs
Market Capitalization
$209.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.04
30 days | 90 days | 365 days | Advanced Chart
Receive PROG News and Ratings via Email

Sign-up to receive the latest news and ratings for Progenity and its competitors with MarketBeat's FREE daily newsletter.


Progenity logo

About Progenity

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.

Headlines

Progenity: Not for the Faint-Hearted - Yahoo Finance
January 18, 2022 |  finance.yahoo.com
Progenity Stock’s Hype Cycle Is Over, It Needs Results
January 6, 2022 |  investorplace.com
See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PROG
Phone
N/A
Fax
N/A
Employees
642
Year Founded
N/A

Sales & Book Value

Annual Sales
$74.31 million
Book Value
($1.96) per share

Profitability

Net Income
$-192.53 million
Net Margins
-583.23%
Pretax Margin
-557.42%

Debt

Price-To-Earnings

Miscellaneous

Free Float
33,896,000
Market Cap
$209.60 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/28/2022
Next Earnings (Estimated)
3/17/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

217th out of 1,417 stocks

Medical Laboratories Industry

6th out of 31 stocks

Analyst Opinion: 3.1Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Progenity (NASDAQ:PROG) Frequently Asked Questions

Is Progenity a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Progenity in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Progenity stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PROG, but not buy additional shares or sell existing shares.
View analyst ratings for Progenity
or view top-rated stocks.

Are investors shorting Progenity?

Progenity saw a decline in short interest in January. As of January 15th, there was short interest totaling 13,000,000 shares, a decline of 15.5% from the December 31st total of 15,380,000 shares. Based on an average daily trading volume, of 42,540,000 shares, the short-interest ratio is presently 0.3 days.
View Progenity's Short Interest
.

When is Progenity's next earnings date?

Progenity is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Progenity
.

How were Progenity's earnings last quarter?

Progenity, Inc. (NASDAQ:PROG) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.01. The company earned $0.18 million during the quarter, compared to analyst estimates of $11.10 million. During the same period in the previous year, the business posted ($1.01) EPS.
View Progenity's earnings history
.

What price target have analysts set for PROG?

6 brokerages have issued 12 month price objectives for Progenity's shares. Their forecasts range from $2.00 to $7.00. On average, they expect Progenity's stock price to reach $4.00 in the next year. This suggests a possible upside of 212.5% from the stock's current price.
View analysts' price targets for Progenity
or view top-rated stocks among Wall Street analysts.

Who are Progenity's key executives?

Progenity's management team includes the following people:
  • Dr. Harry Stylli, Founder, CEO & Chairman (Age 59, Pay $398.82k)
  • Mr. Eric d'Esparbes, Chief Financial Officer (Age 53, Pay $602.67k)
  • Mr. Damon Silvestry, Chief Operating Officer (Age 52, Pay $461.71k)
  • Eric Fox, VP of Fin. & Accounting & Treasurer
  • Dr. Matthew T. Cooper M.B.A., Ph.D., Chief Scientific Officer (Age 48)
  • Mr. Troy Seelye, Chief Information Officer (Age 57)
  • Mr. Clarke Neumann, Sr. VP, Gen. Counsel & Sec. (Age 57)
  • Mr. Hutan Hashemi J.D., Chief Compliance Officer (Age 42)
  • Mr. George Gianakopoulos, Sr. VP of Sales (Age 59)
  • Ms. Robyn Hatton, VP of HR

What other stocks do shareholders of Progenity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progenity investors own include Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Enphase Energy (ENPH), Kandi Technologies Group (KNDI), Trevena (TRVN), ChromaDex (CDXC), Chimerix (CMRX), CorMedix (CRMD), CTI BioPharma (CTIC) and DRDGOLD (DRD).

When did Progenity IPO?

(PROG) raised $100 million in an IPO on Friday, June 19th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Piper Sandler and Wells Fargo Securities served as the underwriters for the IPO and Baird, Raymond James and BTIG were co-managers.

What is Progenity's stock symbol?

Progenity trades on the NASDAQ under the ticker symbol "PROG."

Who are Progenity's major shareholders?

Progenity's stock is owned by a variety of retail and institutional investors. Top institutional investors include Cutler Group LP (0.00%) and XR Securities LLC (0.00%). Company insiders that own Progenity stock include Athyrium Capital Management, L, Damon Silvestry, Harry Stylli and Jeffrey D Alter.
View institutional ownership trends for Progenity
.

Which institutional investors are buying Progenity stock?

PROG stock was purchased by a variety of institutional investors in the last quarter, including Cutler Group LP, and XR Securities LLC. Company insiders that have bought Progenity stock in the last two years include Athyrium Capital Management, L, Damon Silvestry, Harry Stylli, and Jeffrey D Alter.
View insider buying and selling activity for Progenity
or or view top insider-buying stocks.

How do I buy shares of Progenity?

Shares of PROG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Progenity's stock price today?

One share of PROG stock can currently be purchased for approximately $1.28.

How much money does Progenity make?

Progenity has a market capitalization of $209.60 million and generates $74.31 million in revenue each year. The company earns $-192.53 million in net income (profit) each year or ($3.78) on an earnings per share basis.

How many employees does Progenity have?

Progenity employs 642 workers across the globe.

What is Progenity's official website?

The official website for Progenity is www.progenity.com.

Where are Progenity's headquarters?

How can I contact Progenity?

Progenity's mailing address is 4330 LA JOLLA VILLAGE DRIVE SUITE 200, SAN DIEGO CA, 92122. The company can be reached via email at [email protected].


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.